Actors and factors - bridging social science findings and urban land use change modeling

Recent uneven land use dynamics in urban areas resulting from demographic change, economic pressure and the cities’ mutual competition in a globalising world challenge both scientists and practitioners, among them social scientists, modellers and spatial planners. Processes of growth and decline specifically affect the urban environment, the requirements of the residents on social and natural resources. Social and environmental research is interested in a better understanding and ways of explaining the interactions between society and landscape in urban areas. And it is also needed for making life in cities attractive, secure and affordable within or despite of uneven dynamics.\ud The position paper upon “Actors and factors – bridging social science findings and urban land use change modeling” presents approaches and ideas on how social science findings on the interaction of the social system (actors) and the land use (factors) are taken up and formalised using modelling and gaming techniques. It should be understood as a first sketch compiling major challenges and proposing exemplary solutions in the field of interest

Transoral Closed Reduction of Fixed Atlanto-Axial Rotatory-Subluxation (AARS) in Childhood and Adolescence

L

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.

Background There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of early progression on fulvestrant therapy with or without palbociclib, a CDK4/6i.Methods PALOMA-3 was a phase III, multicenter, double-blind randomized controlled trial of palbociclib plus fulvestrant (n = 347) vs placebo plus fulvestrant (n = 174) in patients with endocrine-pretreated estrogen receptor-positive (ER+) breast cancer. Pretreatment plasma samples from 459 patients were analyzed for mutations in 17 genes, copy number in 14 genes, and circulating tumor fraction. Progression-free survival (PFS) was compared in patients with circulating tumor fraction above or below a prespecified cutoff of 10% and with or without a specific genomic alteration. All statistical tests were 2-sided.Results Patients with high ctDNA fraction had worse PFS on both palbociclib plus fulvestrant (hazard ratio [HR] = 1.62, 95% confidence interval [CI] = 1.17 to 2.24; P = .004) and placebo plus fulvestrant (HR = 1.77, 95% CI = 1.21 to 2.59; P = .004). In multivariable analysis, high-circulating tumor fraction was associated with worse PFS (HR = 1.20 per 10% increase in tumor fraction, 95% CI = 1.09 to 1.32; P < .001), as was TP53 mutation (HR = 1.84, 95% CI = 1.27 to 2.65; P = .001) and FGFR1 amplification (HR = 2.91, 95% CI = 1.61 to 5.25; P < .001). No interaction with treatment randomization was observed.Conclusions Pretreatment ctDNA identified a group of high-risk patients with poor clinical outcome despite the addition of CDK4/6 inhibition. These patients might benefit from inclusion in future trials of escalating treatment, with therapies that may be active in these genomic contexts

Towards global volcano monitoring using multisensor sentinel missions and artificial intelligence: The MOUNTS monitoring system

Most of the world&rsquo;s 1500 active volcanoes are not instrumentally monitored, resulting in deadly eruptions which can occur without observation of precursory activity. The new Sentinel missions are now providing freely available imagery with unprecedented spatial and temporal resolutions, with payloads allowing for a comprehensive monitoring of volcanic hazards. We here present the volcano monitoring platform MOUNTS (Monitoring Unrest from Space), which aims for global monitoring, using multisensor satellite-based imagery (Sentinel-1 Synthetic Aperture Radar SAR, Sentinel-2 Short-Wave InfraRed SWIR, Sentinel-5P TROPOMI), ground-based seismic data (GEOFON and USGS global earthquake catalogues), and artificial intelligence (AI) to assist monitoring tasks. It provides near-real-time access to surface deformation, heat anomalies, SO2 gas emissions, and local seismicity at a number of volcanoes around the globe, providing support to both scientific and operational communities for volcanic risk assessment. Results are visualized on an open-access website where both geocoded images and time series of relevant parameters are provided, allowing for a comprehensive understanding of the temporal evolution of volcanic activity and eruptive products. We further demonstrate that AI can play a key role in such monitoring frameworks. Here we design and train a Convolutional Neural Network (CNN) on synthetically generated interferograms, to operationally detect strong deformation (e.g., related to dyke intrusions), in the real interferograms produced by MOUNTS. The utility of this interdisciplinary approach is illustrated through a number of recent eruptions (Erta Ale 2017, Fuego 2018, Kilauea 2018, Anak Krakatau 2018, Ambrym 2018, and Piton de la Fournaise 2018&ndash;2019). We show how exploiting multiple sensors allows for assessment of a variety of volcanic processes in various climatic settings, ranging from subsurface magma intrusion, to surface eruptive deposit emplacement, pre/syn-eruptive morphological changes, and gas propagation into the atmosphere. The data processed by MOUNTS is providing insights into eruptive precursors and eruptive dynamics of these volcanoes, and is sharpening our understanding of how the integration of multiparametric datasets can help better monitor volcanic hazards

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

Background: TAC (docetaxel/doxorubicin/cyclophosphamide) is associated with high incidences of grade 4 neutropenia and febrile neutropenia (FN). This analysis compared the efficacies of four regimens for primary prophylaxis of FN and related toxic effects in breast cancer patients receiving neoadjuvant TAC. Patients and methods: Patients with stage T2-T4 primary breast cancer were scheduled to receive 6-8 cycles of TAC. Primary prophylaxis was: ciprofloxacin 500 mg orally twice daily on days 5-14 (n = 253 patients; 1478 cycles), daily granulocyte colony-stimulating factor (G-CSF) (filgrastim 5 μg/kg/day or lenograstim 150 μg/m2/day) on days 5-10 (n = 377; 2400 cycles), pegfilgrastim 6 mg on day 2 (n = 305; 1930 cycles), or pegfilgrastim plus ciprofloxacin (n = 321; 1890 cycles). Results: Pegfilgrastim with/without ciprofloxacin was significantly more effective than daily G-CSF or ciprofloxacin in preventing FN (5% and 7% versus 18% and 22% of patients; all P < 0.001), grade 4 neutropenia, and leukopenia. Pegfilgrastim plus ciprofloxacin completely prevented first cycle FN (P < 0.01 versus pegfilgrastim alone) and fatal neutropenic events. Conclusion: Ciprofloxacin alone, or daily G-CSF from day 5-10 (as in common practice), provided suboptimal protection against FN and related toxic effects in patients receiving TAC. Pegfilgrastim was significantly more effective in this setting, especially if given with ciprofloxaci